

# Reducing cholesterol could enhance T-cell cancer immunotherapy

May 16 2018

---

Cleveland Clinic researchers have demonstrated for the first time that lowering blood cholesterol levels could enhance the success of a specific type of T-cell immunotherapy in fighting cancer.

The team, led by Qing Yi, MD, Ph.D., of Cleveland Clinic Lerner Research Institute studied T-cell transfer, which has shown great success in recent years. Dr. Yi previously showed that a specific subset of T-cells, called Tc9 cells, have stronger anti-tumor effects than other types of T-cells. In the newly published study, they determined the mechanisms that give Tc9 cells their anti-cancer properties and how those mechanisms might be tweaked to enhance [immunotherapy](#).

Using gene profiling, the researchers discovered that Tc9 cells had much lower levels of intracellular cholesterol than other T-cells. They hypothesized that the reduced cholesterol levels might contribute to the cells' anti-tumor effects. Indeed, when cholesterol-lowering drugs were administered to the cells, anti-cancer pathways were turned on (IL-9 expression and NF-KB signaling). Furthermore, they showed in a tumor-bearing preclinical model that reducing [cholesterol levels](#) prior to immunotherapy led to greater concentrations of IL-9 and better cancer-killing success.

Immunotherapy is a type of cancer treatment that harnesses the power of the human immune system to attack and kill cancer cells. Adoptive T-cell transfer involves transplanting T-cells engineered to recognize a certain type of cancer. Researchers have focused on many different

methods to manipulate and enhance the T-cells' anti-cancer activity, such as transferring [cells](#) at different stages of differentiation or using certain drugs in tandem with immunotherapy.

"Our studies suggest a relatively simple, cost effective way to enhance T-cell transfer therapy," Dr. Yi said. "We hope to test our findings in clinical trials soon."

**More information:** Xingzhe Ma et al, Cholesterol negatively regulates IL-9–producing CD8+T cell differentiation and antitumor activity, *The Journal of Experimental Medicine* (2018). [DOI: 10.1084/jem.20171576](https://doi.org/10.1084/jem.20171576)

Provided by Cleveland Clinic

Citation: Reducing cholesterol could enhance T-cell cancer immunotherapy (2018, May 16) retrieved 19 September 2024 from <https://medicalxpress.com/news/2018-05-cholesterol-t-cell-cancer-immunotherapy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.